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ABSTRACT
Leedy, Megan Renee. M.S. The University of Memphis. May/2010. In Vitro
Evaluation of 87.4% DDA Chitosan coated on Titanium for the Local Release of
Vascular Endothelial Growth Factor. Major Professor: Joel D. Bumgardner, Ph.D.
Dental implants are widely used for the replacement of missing teeth and have a
high success rate, but further enhancement of osseointegration is desired. This
enhancement may be achieved through improved vascularization of surrounding bone.
The aim of this investigation was to determine the potential of chitosan coatings on
titanium to deliver vascular endothelial growth factor (VEGF) to stimulate blood vessel
formation and influence the growth and matrix formation of osteoblastic cells in efforts to
enhance osseointegration.
Chitosan was chemically bonded to titanium via a silane-glutaraldehyde process
and loaded with VEGF. The protein, which was released over three days, improved cell
survival of HUVECs on the chitosan coatings. Saos-2 bone cell cultures were evaluated
for cell growth, expression of ALP, and secretion of osteocalcin and deposition of
calcium. VEGF loaded coatings extended the proliferation period of the cells but did not
further enhance matrix production in comparison to unloaded chitosan coatings.
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PREFACE
The main body of this thesis is a manuscript entitled “Preliminary Evaluation of
87.4% DDA Chitosan Coated on Titanium to Deliver VEGF-121 and Enhance Bone
Mineralization in Vitro.” This manuscript will be submitted to Journal of Biomedical
Material Research Part A.
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CHAPTER 1: INTRODUCTION
Problem Statement
Dental implants of titanium or titanium alloys are commonly used to replace missing
teeth in efforts to restore oral function and aesthetics.1-5 Many dental implant systems
have been developed and successfully placed in mandibular and maxillary locations
within the mouth using one and two stage surgical protocols.2,4 Studies have reported
success rates for dental implants in the maxilla at 92% and the mandible at 94% at 5
years with up to 78% success in the maxilla and 86% success in the mandible after 15
years.4
These implants, however, face challenges because of difficulties from poor bone
quality surrounding the implant as well as the need for extended retention periods of
implants within the body due to the increasing age of our population.3 Implants can fail
in the healthiest bone tissue as well due to infection, excessive implant loading during
osseointegration, or implant loosening over time; and as the demand for dental implants
continues to grow, the number of failures increases as well.5 Aside from these challenges,
there is also a desire to shorten the time needed for implants to integrate within the bone.3
Therefore, there is a need to enhance osseointegration through accelerated bone
formation and maintenance of bone around the implants.

Background and Literary Review
The clinical success of implants is believed to be dependent on the early
osseointegration of the device and this biological fixation is considered to be a
prerequisite for long term success in implant-supported prostheses and for functional
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implant loading.2,5,7 It is believed that the enhancement of early osseointegration will
help to improve the success rates of such implants and is related to the implant’s surface
properties. Therefore, much research is being concentrated on modifying the implant
surface to enhance the integration of implant devices within the hard tissue.1,2,7-10 Current
methods being investigated to modify the titanium surface to achieve a more rapid and
enhanced osseointegration include bioactive coatings and surface roughening by different
methods such as titanium plasma-spraying, grit-blasting, acid-etching, and anodic
oxidation.1,2,7,8 This work will focus on using coatings to modify titanium surfaces since
they provide a method to not only enhance osseointegration, but also a vehicle for the
delivery of therapeutic agents to stimulate and enhance the osseointegration process.

Bioactive Coatings
The process of tissue regeneration may be improved by the use of bioactive coatings or
delivery of bioactive growth factors that stimulate cells to behave in a specific
manner.2,7,9,11 Bioactive coatings made of several materials, including calcium
phosphate, bioactive glass, and proteins, are being examined for their ability to promote
the attachment and growth of bone cells.9 Calcium phosphate coatings, which have been
the focus of much investigation, have shown promise in promoting biological fixation.
This integration occurs through the release of calcium phosphate into the peri-implant
region which causes a biological apatite precipitate to form on the surface of the implant
and serve as a matrix for osteogenic cells to attach and grow.7 While it has been
recognized that calcium phosphate coated implants enhance the bone healing process and
initiate early osseointegration,7,12 their long term success is not significantly different
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than that of non-coated titanium implants and there are concerns of the calcium coatings’
consistency and quality as well as the brittle nature of the coating which can lead to
cracking and loss of coating during implantation.1,9,12,13
Bioactive coatings also offer a vehicle for the delivery of bioactive agents, such as
drugs and/or proteins, to the tissues surrounding the implants. The use of growth factors,
which play important roles in the maintenance of cellular function, have been a major
area of research for the local delivery of bioactive agents for promoting bone formation
around implants. Growth factors such as bone morphogenetic proteins (BMPs) and basic
fibroblast growth factor (bFGF) are investigated for their ability to enhance the early
integration of implants with surrounding bone through their ability to improve osteoblast
differentiation and matrix mineralization due to their oseoinductive properties.11,14 BMPs
are part of the TGF-beta super-family, a highly conserved group of cytokines, and are
known as cartilage and bone-inducing molecules.11,15 They induce the differentiation of
mesenchymal cells toward cells of the osteoblast lineage and therefore increase the
supply of mature osteoblasts and their differentiated function.15 However, along with
increased osteoblastogenesis and the formation of new bone, BMPs also increase
osteoclastogenesis as a secondary consequence which leads to the resorption or
degradation of bone which may lead to poor bone quality.15,16,17 It has been suggested
that BMP-2 coatings may impede osseointegration in oral implants because osteoclast
recruitment may lead to resorption of newly laid bone and overdosage of BMP may
trigger production of intrinsic BMP inhibitors.17 Additionally, complications including
edema, respiratory distress, and hematoma have been associated with the use of BMPs
for cervical spinal fusions.18 The use of BMP has also led to longer hospital stays and
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increased charges in all categories of spinal fusions.18 Therefore, BMPS may not be the
most beneficial bioactive agent in efforts to enhance osseointegration and dental implant
success.
Along with BMPs, FGFs are investigated for use as bioactive agents to enhance
osseointegration. FGFs comprise a family of at least 22 structurally-related proteins
between 20 and 30 kDa that are expressed during the key stages of development and have
long been recognized as important regulators of osteogenesis.19,20 As with BMPs, FGFs
have been shown to affect osteoblast cell proliferation and various stages of osteoblast
differentiation, directly influencing the expression of matrix proteins including alkaline
phosphatase and osteocalcin.20 However, FGFs are multifunctional proteins and key
players in the proliferation and differentiation in a variety of cells and tissues; therefore
FGFs may have too broad of an effect on the surrounding implant site.

Angiogenesis and New Bone Formation
Although only a small component of the process, angiogenesis is a crucial step in the
formation of new bone.21-23 Vasculature provides a mode for the mass transport
requirements of the tissue and the delivery of circulating stem cells that can participate in
bone formation.10,24 It also provides a network which enables cross-talk between
endothelial cells and pre-osteoblasts to direct their differentiation.10,25,26 The formation of
bone is preceded by vasculature invasion and osteogenesis takes place in the vicinity of
newly formed blood vessels.24 Vascularization of peri-implant tissue is a very important
parameter both for the modeling and remodeling of the bone and for the preservation of
bone around a dental implant.27 Therefore, it may be possible that enhanced early
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osseointegration and improved implant success rates may be achieved by promoting
angiogenesis in the tissue surrounding the implant.

Vascular Endothelial Growth Factor
There are a variety of growth factors which have been identified to be positive regulators
of angiogenesis and among such is vascular endothelial growth factor (VEGF). VEGF is
a potent mitogen for endothelial cells and VEGF signaling has been found to be a critical
rate-limiting step in angiogenesis.28,29 It is a homodimeric glycoprotein which is heparinbinding and has several homologs and isoforms identified, with VEGF-121 and VEGF165 being the predominant isoforms.25,28 VEGF has the ability to promote the growth of
vascular endothelial cells derived from arteries, veins and lymphatics and is known to
induce angiogenesis by stimulating and regulating cell proliferation.21,28 Both VEGF121 and VEGF-165 promote angiogenesis contributing to long bone development, cause
permeabilization of blood vessels, and induce proliferation of vascular endothelial cells.30

VEGF and Bone
It has been reported that VEGF not only effects endothelial cells and influences
angiogenesis but also induces alkaline phosphatase (ALP) activity in primary osteoblasts
as well as indirectly inducing proliferation and differentiation of osteoblasts.25,26,29 Many
studies have been completed in which the effect of VEGF on osteoblasts and/or bone
formation was examined. Deckers et al. examined the expression of various homologs of
VEGF (VEGF-A, -B, -C, -D) and their receptors in an in vitro model of osteoblast
differentiation using mouse preosteoblast-like cells. They found VEGF receptors to be
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expressed on the osteoblasts in a differentiation-dependent manner and exogenous
VEGF-A to stimulate bone formation which suggests that VEGF plays an important role
in the regulation of bone remodeling.25 Mayr-Wohlfart et al. also performed in vitro
studies. They investigated the chemoattractive and proliferative properties of human
VEGF-A on primary human osteoblasts in comparison to the effects of human bFGF and
human BMP-2. They demonstrated a dose-dependent chemoattractive effect of VEGF-A
on osteoblast migration as well as increased cell proliferation.29 Through reverse
transcription-polymerase chain reaction analysis (RT-PCR), they also reported VEGF
receptors expression similar to Deckers et al.
In vivo studies have been conducted to evaluate the effect of VEGF on bone
regeneration and fracture repair. Kleinheinz et al. investigated how the controlled release
of rhVEGF influenced angiogenesis and osteogenesis in a mandibular defect model.23
They placed bicortical holes within the lower mandible of white New Zealand rabbits and
either left these defects without filling (control group) or filled them with type-I collagen
which had been complexed with 0.8 µg of rhVEGF-165.23 They had previously reported
that the VEGF was released from the collagen carrier over a 48-hour period, which is the
reported activating period of angiogenesis in wound healing.23 Specimens were collected
throughout a 28-day period and histologic, histomorphometric, and immunohistologic
analyses were performed to evaluate vessel number, cross-sectional area of vessels, as
well as density and area of regenerated bone.23 They found vessel number to increase in
both groups initially but the study group to have persisting high numbers of vessels
compared to the control which showed a regression. They found no significant difference
in the area of newly formed bone between the two groups, but the density of the new
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bone was significantly higher in the group with VEGF. Therefore, it was concluded that
rhVEGF-165 led to more intensive angiogenesis and the increased number of blood
vessels led to improved bone formation and quality.23
Geiger et al. also investigated VEGF-165 coated on collagen sponges for its
ability to efficiently accelerate bone healing of a large defect in New Zealand white
rabbits. They made a gene-activated matrix (GAM), created with either 0.1 or 1mg of a
plasmid coding for human VEGF-165, coated on a collagen sponge and used it to fill
15mm critical size radial defects which were made on the rabbits.26 They reported that
animals in the VEGF group showed significantly more bone regeneration while those
animals with control plasmid (no VEGF) showed no healing of the defect.26 However,
there was no difference between the 0.1 and 1mg VEGF groups.26 This lack of dose
response may be associated with the limited concentrations investigated. They also
reported that the number of vessels at six weeks post surgery was two to three times
greater in the VEGF treated group compared to the control, and significantly fewer
vessels were seen at 12 weeks in both groups in comparison to week 6 which was
interpreted as a progression of multiple small vessels into larger vessels over time.26
While there is much research on the use of VEGF in bone regeneration in fracture
repair and tissue engineering, there are opportunities for modifying implant materials for
the local delivery of the growth factor to promote and maintain their integration in
bone.3,31 The bone quality and implant site are important in the success of implants, and
difficulties arise from poor bone substance in implant surroundings due to osteoporosis,
osteonecrosis associated with the use of bisphosphonates, or from delayed healing
processes due to diseases such as diabetes.3 In such cases, the blood supply and/or
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wound healing are impaired, and it has been shown that osteonecrosis of the jaw from
bisphosphonates reduces the proliferation of endothelial cells.32 Therefore, the proangiogenic properties of VEGF may be beneficial to increase vascularity and bone
quality in implant sites with compromised bone.
Initial research has been conducted incorporating VEGF onto implant materials in
efforts to enhance integration and vascularity. Wolf-Bandstetter et al. modified titanium
alloy with a heparin modified collagen substrate that delivered biologically active VEGF165 in vitro for up 14 days.3 While the system had a positive influence on endothelial
cells, the influence on osteoblasts was not investigated.3 De Giglio et al. were able to
deliver VEGF locally also with P(HEMA–MOEP)-coated titanium over a 48-hour period,
but cell response to the released VEGF was not investigated.31 Therefore while
preliminary investigations have shown the ability to deliver the VEGF locally from
implant coatings, information on the ability of the locally delivered growth factor to
affect cell/tissue behavior is still needed.

Chitosan
A method for the local delivery of VEGF may be accomplished with an arising
biopolymer known as chitosan. Chitosan is currently being investigated as a possible
coating for titanium implants used in orthopaedic/dental applications to promote
osseointegration as well as to deliver growth factors and antibiotics at implant-bone
interface.1,8,9,14,33,34 Chitosan is a de-acetylated derivative of chitin, which is primarily
found in the exoskeletons of shellfish.1,9,33 Chitin is a natural linear polysaccharide of Nacetyl-D-glucosamine units and when 50% of the acetyl groups are removed via
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deacetylation, the copolymer of N-acetyl-glucosamine and N-glucosamine units
remaining is called chitosan.1 Chitosan has shown promise for drug delivery and tissue
engineering, especially in bone applications, because it has demonstrated the ability to be
biodegradable, osteoconductive, and antibacterial which make chitosan an ideal
implantable polymer.1,9,33 Also the degree of deacetylation and the molecular weight of
the chitosan influence the degradation rate of the polymer, and therefore, the adjustments
of such properties provide modes to control the release of bioactive agents from the
coating.34
Previously Bumgardner et al. evaluated coatings made of 91.2% de-acetylated
chitosan chemically bonded to titanium coupons via silane-gluteraldehyde molecules.
Through mechanical tensile testing, they found the chitosan coatings to indeed be
chemically bonded to the titanium, but to have lower bond strengths than those reported
for calcium phosphate coatings.33 Martin et al. modified the coating method by using
toluene versus an aqueous solution when depositing the silane molecules onto the
titanium and an increase in deposited silane molecules on the titanium surface as well as
higher coating bond strengths to levels comparable to calcium phosphate coatings were
reported.8,9 Through in vitro investigation, it was found that the attachment and growth
of osteoblast cells was greater on chitosan coated titanium than on uncoated titanium
samples which indicated the potential of chitosan to be used as bioactive coatings on
titanium for hard tissue implants.33 In vivo studies have also reported on the ability of
chitosan coatings to support osseointegration. Bumgardner et al. implanted chitosan
coated titanium pins unilaterally in the tibia of New Zealand white rabbits and evaluated
the healing and bone formation around the pins in comparison to uncoated titanium pins
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and calcium phosphate titanium pins.1 Through histological evaluations, minimal
inflammatory response and a typical healing sequence of fibrous, woven bone formation,
followed by the development of lamellar bone was indicated by tissues which were in
contact with the chitosan-coated pins.1 These data were sued to support the conclusion
that the chitosan-coated implants would osseointegrate, but there were no data to support
the use of chitosan coatings over the other treatment groups.1
While chitosan has been investigated for the use as a bioactive coating when used
alone, chitosan has also been found to be biodegradable and that it can be used as a
vehicle for drug, protein, and gene delivery.1,14,34 Abarrategi et al. developed chitosan
films in which rhBMP2 was added to the initial chitosan solution prior to casting into
films. They evaluated the protein diffusion from the films, film stability versus in vitro
dissolution, and the biodegradation to study the delivery of the BMP from the coatings.14
A low diffusion rate was observed and it was shown that chitosan films have desirable
features for being a BMP carrier.14 Chitosan hydrogels have also been investigated as
carriers for fibroblast growth factor (FGF) for wound healing applications.36,37 It has
been shown that photocrosslinked chitosan hydrogels gradually release the encapsulated
FGF and prevent inactivation of the protein.36 With the ability of chitosan to deliver both
BMP and FGF in vitro, it has potential to act as a vehicle for the local delivery of VEGF
as well.

Summary
While dental implants are clinically successful, the ability to further promote and
maintain osseointegration is important. An emerging strategy to help bone formation is
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the use VEGF since bone formation is closely related to the formation of blood vessels.
VEGF signaling has been found to be a critical rate-limiting step in angiogenesis as well
as shown to play an important role in the regulation of bone remodeling. Chitosan
materials have been shown to be osteoconductive and can be made into a coating which
may provide an effective delivery vehicle for VEGF. This combination of chitosan
coatings with the local delivery of VEGF may lead to the early osseointegration of
dental/orthopaedic implants and long term maintenance of osseointegration through
increased vascularization. Therefore the hypothesis for this investigation is that chitosan
coatings on titanium act as a vehicle for the local delivery of VEGF to support bone
formation and enhance osseointegration.
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CHAPTER 2: STATEMENT OF RESEARCH OBJECTIVES
Titanium and its alloys are widely used for constructing implants in the dental and
orthopaedic industry because of their biocompatibility, strength, corrosion resistance and
shown success.1,4 While titanium has shown to be able to provide an interface in which
bone can attach and dental implants have shown high success rates, there is a need to
shorten the time to integrate the implant with the bone and to improve the quality of bone
osseointegrated. The enhancement of early osseointegration could improve the success
of implants as well as improve healing and shorten the time within surgeries of dental
implants.
Therefore, methods to modify the surface of implants are looked upon as a mode
to enhance and accelerate osseointegration. We hypothesized that chitosan, chemically
bonded to titanium via a silane-glutaraldehyde process, provides a vehicle for local
delivery of VEGF-121 over a 2-3 day period and stimulates both endothelial and
osteoblastic cell activity in vitro. The rationale behind this research is that VEGF is
known to act as an angiogenic factor and play a key role in the cross-talk between
endothelial cells and osteoblasts21,22,24 while chitosan has shown promise as an
osteoconductive, biodegradable implant coating which can function as local delivery
vehicle for growth factors.1,8,9,14,33,34

Aim I: Produce and evaluate chitosan coatings loaded with vascular endothelial
growth factor-121 (VEGF-121) for release kinetics and coating bond strength. Goal:
Develop coatings on titanium that release biologically active amounts of VEGF for a
minimum of 48 hours and maintain good coating-substrate bond strength. Chitosan
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coatings will be made by solution casting and bonding 87.4% DDA chitosan onto
titanium via a silane-glutaraldehyde process and VEGF will be passively absorbed
into coatings via swelling. The release kinetics of the VEGF from the coatings will
be determined by using ELISA kits to measure the amount of protein released in PBS
at 37C at various time points over an eight day period. The bond strength of the
chitosan coatings to the titanium will be evaluated by performing mechanical tensile
tests. Significance: The data gained will be able to provide information about how
much VEGF should be absorbed into coating in order for a desired amount of protein
be released from the coating over a 48- to 72-hour period and that good bond strength
can be maintained to ensure the coating will not be easily removed during
implantation.

Aim II: Evaluate the effects of the released VEGF and chitosan coatings on the
proliferation of endothelial cells in vitro to determine any angiogenic effects.
Goal: Determine that coatings have a positive effect on cell proliferation and have
angiogenic potential in vitro. Endothelial cells will be cultured over 8 days on the
VEGF loaded coatings in which Live/Dead® assays will be used to evaluate cell
viability and CellTiterGlo assays will be used to quantify cell proliferation at 1, 4, and
8 days. For controls, titanium with chitosan coatings not loaded with VEGF and
titanium coupons without coatings will be used. Significance: By determining that
the coatings have the ability to promote cell growth and have angiogenic capabilities,
the in vitro testing will demonstrate the potential that the coatings may have to
promote angiogenesis in vivo.
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Aim III: Evaluate the effect that the VEGF loaded coatings have on mineralization in
vitro. Goal: Determine that the titanium coupons with chitosan coatings containing
VEGF have no negative effects on the mineralization of osteoblast cells in vitro. The
coatings will be evaluated by culturing osteoblast cells on the coatings for 28 days
and then assaying for cell number, alkaline phosphatase activity, calcium deposition,
and osteocalcin. The assays will be used as indicators of proliferation and matrix
mineralization activity of the osteoblastic cultures. Controls will be coatings without
VEGF and titanium without coatings. Significance: By demonstrating that the
coatings support and enhance osteoblastic proliferation and matrix production in
vitrothe VEGF loaded coatings can be evaluated for their potential to establish
osseointegration.

Overall Significance
Through this investigation, the potential of chitosan coatings to provide a vehicle for
local release of biological active amounts of VEGF and the ability of the released VEGF
to promote endothelial cell migration and osteoblast mineralization will be assessed.
Findings from this study will provide insight into the amount of VEGF that may be
loaded into such coatings to help promote osteoblast matrix production as well as insight
into the prospective ability of such coatings to be used as a method to enhance early
osseointegration of titanium implants and improve long-term success rates.
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ABSTRACT
Dental implants are widely used for the replacement of missing teeth and have a high
success rate, but further enhancement of osseointegration is desired. This enhancement
may be achieved through improved vascularization of surrounding bone. The aim of this
investigation was to determine the potential of chitosan coatings on titanium to deliver
vascular endothelial growth factor (VEGF) to stimulate blood vessel formation and
influence the growth and matrix formation of osteoblastic cells in efforts to enhance
osseointegration. Chitosan was chemically bonded to titanium coupons via a silaneglutaraldehyde process and loaded with 0, 20, 50, or 100ng of VEGF. The protein was
released during a three day period with around 75% (4.44ng/mL/cm2, 11.37ng/mL/cm2,
22.10ng/mL/cm2) of the initial loading being released during the first 12 hours of
incubation and 0.15 ng/mL/cm2, 0.92 ng/mL/cm2, and 1.61 ng/mL/cm2 released between
day 1 and 3 from 20, 50, and 100ng loaded samples respectively. The presence of VEGF
enhanced cell survival on chitosan coatings where HUVECs exhibited low viability on
the unloaded chitosan coatings with an 85% decrease in luminescence values after day 1.
Saos-2 bone cell cultures were evaluated for cell growth via quantification of DNA,
expression of ALP for bone phenotype expression, and secretion of osteocalcin and
deposition of Ca as indicators of bone matrix production. The osteoblastic cells continued
to proliferate over the 28 day period on the VEGF loaded chitosan coatings in contrast to
cells seeded on uncoated titanium that showed a plateau in cell number after two weeks.
While all chitosan coatings exhibited up to a 2-fold enhancement of the alkaline
phosphatase activity and 10-fold increase in calcium deposition, the addition of VEGF
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into the coatings did not show a further enhancement over plain chitosan coatings in
osteoblast matrix production throughout the study.
Keywords: Chitosan, VEGF-121, titanium, osseointegration, mineralization, Saos-2

INTRODUCTION
Dental implants of titanium or titanium alloys are commonly used to replace missing
teeth in efforts to restore oral function and aesthetics.1-5 Many dental implant systems
have been developed and have shown to have high success rates within different
locations in the mouth.2,3 These implants, however, face challenges because of
difficulties from poor bone quality surrounding the implant as well as the need for
extended retention periods of implants within the body due to the increasing age of our
population.3 Implants can fail in the healthy bone tissue as well; and as the demand for
dental implants continues to grow, the number of failures also grows.6 Additionally there
is also a desire to shorten healing time and accelerate osseointegration.3
The clinical success of dental implants is believed to be dependent on the early
osseointegration of the device and is considered to be a prerequisite for long term success
in implant-supported prostheses and for functional implant loading.2,7 One strategy to
accelerate and improve osseointegration is through promoting angiogenesis because of its
important role in tissue healing after injury and as a crucial step in the formation of new
bone.3,8-10 New bone formation is dependent on vascular invasion to provide for the mass
transport requirements of growing/developing tissues and the delivery of circulating precursor cells to the mineralization front.11-13 Blood vessels also enable cross-talk between
endothelial cells and pre-osteoblasts to direct their differentiation.11,14,15 Vascularization
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of peri-implant tissue is a very important parameter both for the remodeling of the bone
and for the preservation of a dental implant after its insertion.16 Therefore, improving
angiogenesis in the tissues surrounding a dental implant may provide an effective method
to enhance early osseointegration and improve implant success rates.
There are a variety of growth factors which have been identified to be positive
regulators of angiogenesis and among such is vascular endothelial growth factor (VEGF).
VEGF is a potent mitogen for endothelial cells and VEGF signaling has been found to be
a critical rate-limiting step in angiogenesis.17,18 It is a homodimeric glycoprotein which is
heparin-binding and has several homologs and isoforms identified with VEGF-121 and
VEGF-165 being the predominant isoforms.14,17 It has been reported that VEGF also
induces alkaline phosphatase (ALP) activity in primary osteoblasts as well as indirectly
inducing proliferation and differentiation of osteoblasts.14,15,18 While VEGF has shown
promise in promoting bone growth in tissue engineering and fracture defect models,10,13,15
more research is necessary to investigate the ability of VEGF to enhance osseointegration
when implant materials are modified to deliver the growth factor locally.
The method for the local delivery of VEGF can be addressed with a biopolymer
known as chitosan, which has been investigated as a possible coating for titanium
implants used in orthopaedic/dental applications to promote osseointegration.1,20,21,22
Chitosan is a de-acetylated derivative of chitin, which is a natural linear polysaccharide
of N-acetyl-D-glucosamine units primarily found in the exoskeletons of shellfish.1,19,20
Chitosan has shown promise for drug delivery and tissue engineering, especially in bone
applications, because it has demonstrated the ability to be biodegradable,
osteoconductive, and antibacterial.1,19,20

Chitosan can chemically bond to titanium via a
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silane-gluteraldehyde process19-21 and chitosan coatings have shown to increase
osteoblast cell attachment and growth in comparison to uncoated titanium samples and to
be osseointegrated in rodent models indicating the potential of chitosan to be used as a
bioactive coating on titanium for hard tissue implants.1,21-23
The objective of this study was two-fold: to evaluate the use of 87.4%
deacetylated chitosan films, bonded to titanium via a silane-glutaraldehyde process, to
deliver biologically active VEGF-121 locally; and to the evaluate the responses of human
umbilical vein endothelial cells (HUVEC) as well as osteoblastic cells to the coatings in
vitro.

MATERIALS AND METHODS
Coating Preparation
Titanium coupons (Ti; Titanium Industries, commercially pure ASTM F67; 1.3cm x
1.3cm x 0.1cm or 3.2cm x 2.5cm x 0.1cm) were wet sanded up to 1200 grit SiC paper;
ultrasonically cleaned with deionized water, acetone and ethanol for 5 minutes each;
passivated in 30% nitric acid; and then rinsed with deionized water. Chitosan (87.4% deacetylated, MW approx 1.2 x 105 , Vanson, Redmond, WA) at 1 wt% in 1% acetic acid
was solution cast and bonded via silane-glutaraldehyde reactions as previously
described.19-21 Samples were sterilized by ethylene oxide gas prior to experiments.
Human vascular endothelial growth factor-121 (VEGF-121; PeproTech, Rocky
Hill, NJ) was reconstituted in sterile PBS at four concentrations;0 ng/mL, 200 ng/mL,
500 ng/mL, and 1µg/mL. Coated titanium coupons were placed in individual wells of
twelve-well plates and hydrated with 100µL of one of the four VEGF concentrations,
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loading each coating with either 0ng (C0), 20ng (C20), 50ng (C50), or 100ng (C100) of
VEGF-121. The samples were incubated for 24 hours at room temperature, rinsed with
sterile PBS to remove any unabsorbed protein, and then directly used for in vitro testing.

Coating Characterization
I. Coating Bond Strength: Bulk adhesion tests, based on modified ASTM standard,
were performed using an electrical-mechanical Instron Model 4465 load frame
(Instron Corporation, Norwood, MA) with a 5000 N load cell. Aluminum pins
(11.41mm Ø) were glued to the coating surface using Loctite Prism 454 Instant Gel
Adhesive, dead weighted to ensure contact, and cured for 24 hrs at room
temperature to allow the glue to set. The aluminum pins and samples were secured
to the load frame and pre-loaded in tension with 5.0N to prevent compression forces
being included in the calculations. Tests were run at a constant crosshead
displacement of 0.50 mm/min until failure occurred by a break in the coatingsubstrate, coating glue, or glue-pin interface. The maximum load before the breach
of the interface was used to calculate the maximum tensile stress, reported in MPa.
Results were presented as average maximum tensile strength ± standard deviation
(n = 8). Figure 1 shows testing set-up.
II. Protein Release Kinetics: The coated titanium samples were placed in twelve well
plates and covered with 2 mL of sterile PBS and incubated at 37oC. The solution
was sampled and completely replaced after 1 hr, 6 hrs, 12 hrs, 1 day, 3 days, 5 days,
and 8 days in aseptic conditions. The collected eluates were frozen at -20oC until
the end of the elution study. For analysis eluates were diluted 50-fold in PBS and
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the concentration of VEGF-121 released at each time point was quantified with
Human VEGF ELISA kit (PeproTech, Rocky Hill, NJ) according to manufacturer’s
directions. Readings from the chitosan coated titanium samples loaded with just
PBS served as a baseline and were subtracted from the readings obtained from
coatings loaded with VEGF.

Endothelial Cell Proliferation and Viability
Human umbilical vein endothelial cells (HUVEC; ATCC, Manassas, VA) were grown in
complete medium of Endothelial Basal Medium supplemented with 0.2% bovine brain
extract (BBE), 5 ng/ml rhEGF, 10 mM L-glutamine, 0.75 U/ml heparin sulfate, 1 μg/ml
hydrocortisone, 50 µg/ml ascorbic acid, 2% Fetal Bovine Serum (ATCC, Manassas, VA),
and antibiotic comprised of 20 IU/mL penicillin, 20 µg/mL streptomycin, and 50 ng/mL
amphotericin-B (MP Biomedicals). The cells were maintained in an incubator at 37oC
with 100% humidified 5% CO2 atmosphere. The day before subculturing cells, the
supplemented media was replaced with assay media which consisted of the Basal
Medium supplemented only with the antibiotic solution and 10% Fetal Bovine Serum
(Hyclone, Logan, UT). At passage eight, confluent cells were subcultured and seeded
onto the chitosan test and titanium control samples in 12 well plates at 5 x 103 cells/cm2
in 2 mL of assay media. Cells were grown for eight days with media change at day 3 and
6. Cell growth was estimated using the CellTiter-Glo Assay kit (Promega, Madison, WI)
which is based on the quantification of ATP present in cultured cells by the luciferinluciferase reaction. At 1, 4, and 8 days, samples (n=4) were rinsed with 1 mL of PBS and
then transferred to empty wells of a 12 well plate. The coupons were then covered with
500 µL of media and 500 µL of CellTiter-Glo reagent, gently shaken for 2 minutes to
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lyse the cells, and then allowed to rest at room temperature for 10 minutes. 200 µL of the
media/CellTiter-Glo reagent was then placed in a 96 well plate with opaque walls in
duplicate. The luminosity of the reaction was recorded using a microplate reader
(FLx800, Bio-Tek Instruments, Inc., Winooski, VT) with measurements taken at a
sensitivity of 150 and with a 590/35 filter. Additionally, the viability of the HUVECs
after four and eight days on test and control samples (n=1) was qualitatively determined
using a BioQuant confocal microscope and the LIVE/DEAD® stain (Molecular Probes,
Eugene, OR, USA). In the confocal microscope, live cells fluoresce green and dead cells
fluoresce red.

In vitro Mineralization
Mineralization studies were performed using Saos-2 osteosarcoma cells (ATCC,
Manassas, VA). Cells were grown in complete medium of 90% HyQ McCoy’s 5a– 10%
Fetal Bovine Serum supplemented with 1.5 mm L-Glutamine, 2.2 g/L Sodium
Bicarbonate (Hyclone, Logan, UT), and antibiotic comprised of 100 IU/mL penicillin,
100 µg/mL streptomycin, and 250 ng/mL amphotericin-B (MP Biomedicals). The cells
were maintained in an incubator at 37oC with 100% humidified 5% CO2 atmosphere.
Quadruplicate samples of chitosan coatings loaded with the four different VEGF
concentrations (0ng, 20ng, 50ng, and 100ng VEGF/sample) as well as passivated,
uncoated titanium samples were placed into individual wells of twelve well plates for
each time point. Cells, at passage five, were seeded at 104 cells/cm2 in 2 mL of
mineralizing media (complete growth media additionally supplemented with 5µM
ascorbic acid and 10mM β-glycerophosphate). Throughout a 28 day study, cultures were
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evaluated for cell growth via quantification of DNA, expression of ALP for bone
phenotype expression, and secretion of osteocalcin and deposition of Ca as indicators of
bone matrix production.
For cell growth and ALP expression, medium was removed and cells lysed in
molecular grade water and ultrasonication (Sonic Dismembranor, 10s/well). Lysates were
collected at 1, 3, 5, 7, 10, 14, 21, and 28 days culture and stored at -20°C until analysis.
DNA in the lysate was quantified with the use of Quant-iT™ PicoGreen® dsDNA
Reagent Kit (Molecular Probes, Eugene, OR) and measuring the florescence with a BioTek FLx800 (Bio-Tek Instruments, Inc., Winooski, VT) at 485nm excitation and 528nm
emission. ALP was determined based on the p-nitrophenyl phosphate reaction.
Absorbance of samples was compared to an ALP standard curve, normalized to DNA and
recorded as μg ALP/μg dsDNA.
For determination of CaP deposition on days 7, 14, 21, and 28, samples were
measured for Ca via the o-Cresolphthalein (OCP) method. After cell lysis, samples were
digested with 0.05M HCL at 4°C for 24hrs, and then stored at -20°C until analysis.
Samples were analyzed for calcium using a calcium reagent set (Pointe Scientific, Inc.,
Brussels, Belgium) and reading the absorbance with a colorimetric plate reader set at
570nm. The absorbance of the samples were compared to calcium standards prepared in
the same 0.5M HCl solution which was used to digest the calcium from the samples.
Calcium was also measured for chitosan coatings not seeded with cells for a baseline
calcium measurement and was subtracted from results.
A Mid-Tact Human Osteocalcin ELISA Kit (Biomedical Technologies,
Stoughton, MA) was used according to manufacturer’s protocol to quantify osteocalcin in
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the supernatant which was obtained from samples on days 1, 3, 5, 7, 10, 14, 21, and 28.
Osteocalcin measured in the mineralization media was subtracted from results. At each
time point the results were compared between treatments to determine whether the
chitosan coatings loaded with VEGF had an effect on the ability of the osteoblastic cells
to proliferate and lay down bone matrix.

Statistical Analyses
Analysis of variances (ANOVA) test with SNK post-test was used to determine statistical
differences in cell proliferation and mineralization studies. A p-value < 0.05 was
considered significant.

RESULTS
Coating Characterization
The maximum stress recorded during bulk adhesion testing was 4.59 ± 0.70 MPa (mean ±
standard deviation). The maximum tensile stress was not significantly different than the
glue strength (4.72 ± 0.97 MPa) measured from removing pins glued directly onto
titanium. Observations of the coatings after tensile testing showed that the failure was
between the aluminum pins and the chitosan coatings; the chitosan did not break from the
titanium. The chitosan coatings were chemically bonded to the titanium stronger than the
strength of the glue.
Figure 2 shows the results of the VEGF-121 released from the chitosan coatings
in vitro over an eight day period. There was an initial burst release within the first 12
hours in which approximately 75% of the initial loaded VEGF was released
(4.44ng/mL/cm2, 11.37ng/mL/cm2, 22.10ng/mL/cm2). The VEGF was released for only

24

3 days with 0.15ng/mL/cm2, 0.92ng/mL/cm2, and 1.61ng/mL/cm2 being released between
day 1 and day 3 from C20, C50, and C100 test samples respectively. By day 3,
approximately 90-95% of all loaded VEGF has been released from the coatings. The
released concentrations of VEGF were dependent on the loaded amount, but the
percentage of release was independent.

Endothelial Cell Proliferation
Samples were evaluated for the ability to promote the proliferation of HUVEC cells in
vitro over an eight day period using CellTiter Glo to estimate cell growth and Live/Dead
staining to evaluate the viability of the cells. Figure 3 shows the CellTiter Glo results of
the 8 day HUVEC proliferation study. The HUVECs did not proliferate on any of the
substrates and cell numbers actually decreased based on luminescence values over the 8
day study. On day 1, there was no significant difference in cells based on luminescence
values between the uncoated titanium, C0, C20, and C50 test coatings; C100 coatings,
though, showed significantly lower values than the uncoated Ti. The cell number, based
on luminescence values, remained relatively constant between day 1 and day 4 on the
VEGF loaded coatings (C20, C50, C100) but significantly decreased after day 4. The
uncoated Ti and chitosan coatings unloaded with VEGF (C0) showed a drop in cell
number after day 1. Unloaded chitosan coatings (C0) had significantly less number of
cells on day 4 than the titanium controls and the VEGF loaded chitosan coatings which
was in agreement with the viability staining which showed that the cells on uncoated
titanium (Ti control) and VEGF loaded chitosan coatings (C20, C50, C100) to have
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greater viabilities based on the predominately green fluorescence seen on the samples as
compared to the unloaded chitosan coatings (C0), which exhibited low viabilities.

Mineralization Study
A 28-day mineralization study was completed on the sample groups in which cell
proliferation, ALP activity, calcium deposition, and osteocalcin production were
quantified. The total cell number, as measured by DNA content, over the 28-day study is
shown in Figure 4. During the first ten days, cell proliferation was significantly greater on
the uncoated titanium controls, but then the proliferation plateaued on the titanium
samples after day 10. Cell proliferation on all the chitosan coated samples, however,
continued to increase during the whole 28 days. No difference in cell proliferation was
observed between any of the surfaces after 14 and 21 days of incubation. On day 28, the
chitosan coatings loaded with 50 ng and 100 ng of VEGF-121 had significantly more
cells than the titanium controls and the unloaded chitosan coatings (P<0.05).
The ALP results normalized to DNA are shown in Figure 5. The ALP activity of
the Saos-2 cells was significantly higher on all the chitosan coated titanium samples on
days 1, 3, 28 than the uncoated control. The C20 samples had more ALP activity
compared to all other treatment groups at days 1 and 28. There was no significant
difference in ALP activity for any substrates between day 3 and day 21 of incubation.
The calcium results normalized to DNA are shown in Figure 6. Titanium controls
had significantly less calcium than all other sample groups during the first 21 days. On
day 7, the C20 coatings had significantly more calcium deposition than the other loaded
chitosan coatings (C50 & C100), but not the unloaded chitosan coatings (C0). C0
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samples had significantly more calcium deposition than all other substrates on days 10,
21, and 28.
Figure 7 shows the osteocalcin results normalized to the DNA. There was no
significant difference in the osteocalcin production among any of the sample groups on
days 1, 3, 7, 21, and 28. While not statistically significant, the C50 and C100 test
coatings did show an increase in osteocalcin expression on day 1 an day 3. After 5 days,
the C0 and C100 samples had significantly higher osteocalcin production than the
uncoated Ti, C20 and C50 samples. At day 10, C0 and C20 samples had higher
osteocalcin production than the Ti controls and the C100 samples. At day 14, the
unloaded chitosan coatings (C0) had significantly higher osteocalcin production than all
treatment groups and C20 had higher osteocalcin production than C100.

DISCUSSION
The aim of this study was to investigate the use of chitosan films bonded to titanium for
the local delivery of VEGF-121 for orthopaedic, dental and craniofacial implants. The
results of the mechanical testing indicated that the chitosan coating was bonded to the
titanium by the silane-glutaraldehyde molecules. The actual bulk adhesion strength of
chitosan on titanium could not be concluded from this investigation because the coatingtitanium interface was not broken. It can only be concluded that the bond between the
chitosan and titanium was stronger than the 4.6 MPa bond strength of the glue. This
bond strength is higher than the bond strength of chitosan coatings produced by
Bumgardner et al in which an ethanol solution was used to deposit the silane molecules
versus the toluene used in this study.21 This improved strength was also seen by Martin

27

et al in which higher maximum tensile stresses were reported than found during this
investigation.20
The bonded coatings were able to absorb the VEGF-121, and the VEGF was
released from the chitosan coatings in this investigation for only 3 days in culture. This
is less than 14-18 day release profiles of some substrates,3,24 but was comparable to
poly(HEMA–MOEP) coatings.25 The three days release also met the minimum 48 hour
period, a reported time frame for activating angiogenesis in wound healing/tissue
regeneration.10,26 Approximately 75% of the VEGF, however, was released within the
first 12 hours of incubation. This initial burst release from the chitosan was not desired.
Heparin-collagen coatings on titanium released higher levels of VEGF in the first 24
hours but were loaded with more VEGF than used in this study, and resulted in the
release of VEGF for 14 days.3 The rapid release may be attributed to the passive method
of loading the VEGF-121 into the chitosan.
HUVECs were cultured on the uncoated titanium controls as well as the unloaded
and loaded chitosan to evaluate effects on proliferation. During the proliferation study,
cells were cultured in an assay medium (described in methods) in order to determine the
influence of the released VEGF. Without other growth factors such as bovine brain
extract and epidermal growth factor that are normally found in endothelial growth
medium, titanium was not able to promote proliferation in vitro, nor was proliferation
promoted in the presence of VEGF-121 on the chitosan coatings either. The presence of
VEGF did improve the viability of the HUVEC on the chitosan coated samples while
chitosan coatings without VEGF showed low viability. The cell number significantly
decreased on the chitosan coatings after day 4, which could be due to VEGF no longer
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being present within culture since it was shown to be released within the first three days.
The lack of cell growth directly on the substrate may be a desirable outcome since the
activation, proliferation, and sprouting of endothelial cells should not be initiated directly
on the implant surface in vivo.3 . The low viability on the unloaded chitosan contradicts
the findings of Wang et al. in which endothelial cells attached and grew on substrates
containing chitosan.27 However, complete growth medium was used since the effects of
VEGF were not being investigated. Therefore the loss in viability and decrease in growth
may be attributed more to the lack of growth factors in the medium than the substrate for
Day 1 shows good cell attachment of HUVECs on the chitosan substrate which supports
previous studies. Since the chitosan did not adversely affect the cells in the presence of
the growth factor, chitosan may be applicable for delivery of angiogenic factors in vivo.
A 28-day mineralization study was completed using Saos-2 cells to evaluate the
coatings ability to promote osteoblast matrix production by quantifying cell number,
alkaline phosphatase activity, calcium deposition, and osteocalcin production. In the
beginning of the study, the osteoblastic cell proliferation was greater on the uncoated
titanium controls, and then plateaued after day 10 as expected since proliferation is down
regulated as cells progress into the mineralization stage.28 The cells on the chitosan
coated titanium samples, however, continued to increase in cell number over the entire 28
days. The unloaded chitosan coated titanium samples did not have a positive influence
on cell proliferation in comparison to the titanium controls. The incorporation of VEGF
into the coatings, though, exhibited an overall dose-dependent affect on cell proliferation
with C50 and C100 samples having significantly higher cell numbers than the uncoated
titanium and unloaded chitosan coatings after 28 days. Although the VEGF did not
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promote a rapid growth rate initially, these findings are in agreement that exongenous
VEGF is a regulator of osteoblast survival, inhibiting programmed cell death and
promoting osteoblast proliferation.18,29
Alkaline phosphatase activity has long been associated with biological
mineralization.30 In agreement with Saos-2 cell behavior,30 the ALP activity dropped
after cell seeding and then increased thereafter on all substrates. The chitosan coated
titanium samples (loaded and unloaded) had a greater ALP activity in the beginning of
the study than the uncoated titanium samples suggesting a higher proportion of mature
osteoblastic phenotype. This increased ALP activity is consistent with previous studies
which support chitosan as a potential bioactive coating for orthopaedic applications.1,20-22
As shown with human mesenchymal stem cells,24 there was no significant difference in
ALP activity in the presence or absence of VEGF-121 in this study. It has previously
been shown that VEGF positively influences ALP activity of osteoblastic cells in vitro
when used in conjunction with bone morphogenetic proteins by a synergistic effect, but
not when used alone.24,31
Based on the temporal expression of cell growth and osteoblast phenotype-related
genes during the development of the osteoblast phenotype, increased detection of ALP is
seen following the down-regulation of proliferation as cells transition into a more mature
osteoblastic phenotype.28 This sequence was seen on the titanium coupons which
showed a peak in ALP expression around day 14 after cell growth plateaued. Chitosan
coatings had a delay in ALP expression with a peak around day 21. The VEGF loaded
chitosan test samples did not reach a peak in ALP expression during the 28 days, but high
levels of ALP expression were reached and the cells were still in a highly proliferative
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state. Combination of proliferation and maturation of osteoblastic cells may be beneficial
in enhancing osseointegration.
Similarly with the early ALP activity, the calcium deposition was enhanced by
coating the titanium in chitosan, but incorporation of VEGF did not further improve
calcium deposition. On days 21 and 28, the VEGF loaded coatings showed decreased
calcium deposition in comparison to unloaded chitosan coatings which may be attributed
to the cells remaining in a proliferative state. However, while the cells on the VEGF
loaded coatings continued to grow, the VEGF loaded coatings did have a higher calcium
deposition than the uncoated titanium samples.
Osteocalcin production is used as a biomarker for the bone formation process and
therefore was quantified during the mineralization study. Due to high variation, it is
difficult to make conclusions about the effect of the VEGF; however, at early time points
there was a non-significant increase of osteocalcin expression when the high VEGF
concentrations were present. Osteocalcin is induced post-proliferatively at the onset of
mineralization28 and the early expression suggests that the VEGF induced early
mineralization in vitro. It should be noted that the high levels of osteocalcin production
shown on the VEGF loaded samples correlates with the delay in cell proliferation shown
in this study although it is unclear why this may occur. Late in the study VEGF loaded
coatings did not effect osteocalcin expression which is similar to a previous study in
which VEGF was transfected into periosteum cells and analyzed in vivo and no increase
in osteocalcin or ALP was reported although an increase in bone area was shown
compared to non-transfected cells.31
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CONCLUSIONS
In this preliminary study, chitosan was bound to titanium and released VEGF-121 in vitro
over a three day period. The VEGF loaded chitosan coatings promoted cell survival but
did not promote proliferation since HUVECs did not proliferate on any substrate. The
released VEGF increased osteoblast-like cell proliferation and an early osteocalcin
expression, but did not increase ALP activity or calcium deposition as compared to
unloaded chitosan controls. The incorporation of VEGF into the coatings did provide a
mechanism for the osteoblast cells to increase ALP activity and osteocalcin expression
while cells continued to proliferate which may be beneficial for enhancing
osseointegration. Future studies with the pre-osteoblast cells, the co-culture of
endothelial and osteoblastic cells in vitro, as well as in vivo studies would be beneficial to
better evaluate the potential of VEGF releasing chitosan coatings to promote
osseointegration. Also methods to minimize the burst release of the growth factor and
improve the elution profile are needed. Overall, the VEGF loaded chitosan coatings
promoted bone formation in vitro and demonstrated potential for dental/orthopaedic
implant applications.
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Figure 1. Set-up of bulk adhesion test with sample loaded onto test frame.
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Figure 2. Released VEGF from chitosan coatings loaded with 20ng (C20), 50ng (C50),
and 100ng (C100) of VEGF-121. Values represent means ± standard deviation (n=4). ‡
denotes a statistically significant difference from all other substrates at time point (p <
0.05).
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Figure 3. Cell proliferation of HUVECs seeded on uncoated Ti controls, unloaded
chitosan coatings (C0), and loaded chitosan coatings with VEGF-121 (C20, C50, C100).
Values represent means ± standard deviation (n=4). † denotes a statistically significant
difference (p < .05). ‡ denotes a statistically significant difference from all other
substrates at independent time (p < .05). * denotes a significant difference of substrate
from previous time point (p < .05).
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Figure 4. Cell proliferation of Saos-2 cells seeded on uncoated Ti controls, unloaded
chitosan coatings (C0), and loaded chitosan coatings with VEGF-121 (C20, C50, C100).
Values represent means ± standard deviation (n=4). † denotes a statistically significant
difference (p < .05). ‡ denotes a statistically significant difference from all other
substrates (p < .05).
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Figure 5. Alkaline phosphatase (ALP) activity of Saos-2 cells seeded on uncoated Ti
controls, unloaded chitosan coatings (C0), and loaded chitosan coatings with VEGF-121
(C20, C50, C100). Values represent means ± standard deviation (n = 4). † denotes a
statistically significant difference (p < .05). ‡ denotes a statistically significant difference
from all other substrates (p < .05).
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Figure 6. Calcium deposition of cultures on uncoated Ti controls, unloaded chitosan
coatings (C0), and loaded chitosan coatings with VEGF-121 (C20, C50, C100). Values
represent means ± standard deviation (n = 4). † denotes a statistically significant
difference (p < .05). ‡ denotes a statistically significant difference from all other
substrates (p < .05).
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Figure 7. Osteocalcin production of cultures on uncoated Ti controls, unloaded chitosan
coatings (C0), and loaded chitosan coatings with VEGF-121 (C20, C50, C100). Values
represent means ± standard deviation (n = 4). † denotes a statistically significant
difference (p < .05). ‡ denotes a statistically significant difference from all other
substrates (p < .05).
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CHAPTER 4: CONCLUSIONS
The aim of this investigation was to evaluate the ability of chitosan coatings on titanium
to locally deliver VEGF and stimulate both endothelial cell proliferation as indication of
angiogenesis and osteoblastic cell matrix production as indicator of osseogenesis for the
ultimate goal of enhanced osseointegration. Chitosan was chemically bonded to titanium
via a silane-glutaraldhyde process and the coatings absorbed 0-100ng of VEGF-121.
VEGF was released from the coatings over 3 days with 75% of initial concentrations
(7.5ng/mL, 19.2ng/mL, 37.4ng/mL) released during the first 12 hours regardless of initial
loading followed by a much lower release, 0.2ng/mL, 1.6ng/mL, 2.5ng/mL repsectivevly,
between day 1 and 3. The presence of VEGF enhanced the HUVEC survival on the
chitosan coated titanium whereas the viability of HUVECs was low on the unloaded
chitosan coatings. The VEGF increased the proliferation of osteoblastic cells which were
seeded onto the coatings as the cells continued to proliferate throughout a 28 day
mineralization study. While the chitosan coatings enhanced the alkaline phosphatase
activity and calcium deposition in comparison to titanium controls, the addition of VEGF
into the coatings did not show a further enhancement in osteoblast matrix production
based on osteocalcin production throughout the study.
The coatings were able to locally deliver VEGF-121 in vitro which promoted
HUVEC cell survival on the chitosan coated samples. While the VEGF did not further
enhance the matrix production overall in comparison to unloaded chitosan coatings, the
VEGF did extend the proliferative state of the osteoblastic cells. The increased cell
number while matrix production is occurring may be beneficial in the enhancement of
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osseointegration of dental implants, but more testing is needed to further investigate the
potential of this strategy.
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CHAPTER 5: FUTURE WORK
Further work needs to be completed to fully evaluate the potential of these coatings to
enhance osseointegration. The activity of the VEGF is dependent on concentration;
therefore further investigations into the optimum VEGF concentration needed to be
delivered will be completed. Along with altering the initial concentrations loaded into
the coatings, other methods to load the protein into the coating will be explored to limit
the burst release such as incorporating the protein into the chitosan solution prior to
casting or cross-linking the chitosan. By controlling the initial amount of protein loaded
into the coatings as well as the amount that is released, the optimum VEGF concentration
for maximal results can be determined. Since the activity is also dependent on the
isoform of VEGF used as well as the concentration, the use of other isoforms, such as
VEGF-165, will be looked upon to determine the ideal isoform for this application.
The angiogenic ability of the VEGF needs to be further investigated with HUVEC
migrations studies since we are interested in the angiogenic activity surrounding the
implant site and not on the implant surface itself. Further investigation on the influence of
the delivered VEGF on the osteoblastic cells will also be explored by evaluating the
ability of the protein to induce migration of osteoblast cells as well the production of
collagen. To fully evaluate the potential of such coatings, however, more realistic models
need to be incorporated since the mechanism in which VEGF works within the body is
dependent on the interaction of various components such as the cross-talk between
endothelial cells and osteoblast cells. The co-culture of the two cells on the chitosan
coatings may provide better insight to accurately evaluate whether chitosan coatings that
deliver VEGF locally would be beneficial.
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